RESEARCH

Open Access

<figure><img src="image_1.png" /></figure>

Check for
updates

# Myocardial transcriptomic analysis of diabetic patients with aortic stenosis: key role for mitochondrial calcium signaling

Maelle Cherpaz<sup>2,6†</sup>, Emmanuelle Meugnier<sup>2†</sup>, Gaultier Seillier<sup>1†</sup>, Matteo Pozzi<sup>5</sup>, Romain Pierrard<sup>3</sup>, Simon Leboube<sup>1,2</sup>, Fadi Farhat<sup>5</sup>, Marco Vola<sup>5</sup>, Jean-François Obadia<sup>5</sup>, Camille Amaz<sup>6</sup>, Lara Chalabreysse<sup>4</sup>, Chloe May<sup>6</sup>, Stephanie Chanon<sup>2</sup>, Camille Brun<sup>2</sup>, Lucas Givre<sup>2</sup>, Gabriel Bidaux<sup>2</sup>, Nathan Mewton<sup>2,6</sup>, Genevieve Derumeaux<sup>1,7,8</sup>, Cyrille Bergerot<sup>1,2</sup>, Melanie Paillard<sup>2*†</sup> and Helene Thibault<sup>1,2*†</sup>

**Abstract**

**Background** Type 2 diabetes (T2D) is a frequent comorbidity encountered in patients with severe aortic stenosis (AS), leading to an adverse left ventricular (LV) remodeling and dysfunction. Metabolic alterations have been suggested as contributors of the deleterious effect of T2D on LV remodeling and function in patients with severe AS, but so far, the underlying mechanisms remain unclear. Mitochondria play a central role in the regulation of cardiac energy metabolism.

**Objectives** We aimed to explore the mitochondrial alterations associated with the deleterious effect of T2D on LV remodeling and function in patients with AS, preserved ejection fraction, and no additional heart disease.

**Methods** We combined an in-depth clinical, biological and echocardiography phenotype of patients with severe AS, with (n = 34) or without (n = 50) T2D, referred for a valve replacement, with transcriptomic and histological analyses of an intra-operative myocardial LV biopsy.

**Results** T2D patients had similar AS severity but displayed worse cardiac remodeling, systolic and diastolic function than non-diabetics. RNAseq analysis identified 1029 significantly differentially expressed genes. Functional enrichment analysis revealed several T2D-specific upregulated pathways despite comorbidity adjustment, gathering regulation of inflammation, extracellular matrix organization, endothelial function/angiogenesis, and adaptation to cardiac hypertrophy. Downregulated gene sets independently associated with T2D were related to mitochondrial respiratory chain organization/function and mitochondrial organization. Generation of causal networks suggested

Full list of author information is available at the end of the article

BMC

© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<footnote>†Maelle Cherpaz, Emmanuelle Meugnier and Gaultier Seillier share the first authorship.</footnote>

<footnote>†Melanie Paillard and Helene Thibault share the last authorship and correspondence.</footnote>

<footnote>*Correspondence:
Melanie Paillard
melanie.paillard@univ-lyon1.fr
Helene Thibault
helene.thibault@chu-lyon.fr</footnote>
a reduced Ca²⁺ signaling up to the mitochondria, with the measured gene remodeling of the mitochondrial Ca²⁺ unipporter in favor of enhanced uptake. Histological analyses supported a greater cardiomyocyte hypertrophy and a decreased proximity between the mitochondrial VDAC porin and the reticular IP3-receptor in T2D.

**Conclusions** Our data support a crucial role for mitochondrial Ca²⁺ signaling in T2D-induced cardiac dysfunction in severe AS patients, from a structural reticulum-mitochondria Ca²⁺ uncoupling to a mitochondrial gene remodeling. Thus, our findings open a new therapeutic avenue to be tested in animal models and further human cardiac biopsies in order to propose new treatments for T2D patients suffering from AS.

**Trial registration** URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01862237.

**Graphical abstract**

<figure><img src="image_2.png" /></figure>

**Cardiac Function**

<figure><img src="image_3.png" /></figure>

<figure><img src="image_4.png" /></figure>

LV mass

<figure><img src="image_5.png" /></figure>

LVFP

<figure><img src="image_6.png" /></figure>

GLS

**Gene expression**

<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /></figure>

Hypertrophy

<figure><img src="image_9.png" /></figure>

ETC

<figure><img src="image_10.png" /></figure>

MICU1/MCU
ratio

<figure><img src="image_11.png" /></figure>

Membrane
organization

**Myocardial Histology**

<figure><img src="image_12.png" /></figure>

<figure><img src="image_13.png" /></figure>

CM
diameter

<figure><img src="image_14.png" /></figure>

<figure><img src="image_15.png" /></figure>

Structural
MAM Ca²⁺
coupling

**Keywords** Pressure overload, Mitochondria, RNAseq, MAM, Mitochondria-associated membranes, MICU1, MCU, HFpEF

**Background**

Type 2 diabetes (T2D) is an increasingly prevalent health problem in Western societies, affecting at least 110 million people in Europe and North America [1], and expected to reach more than 10% of the worldwide population in 2045. Beyond its huge socio-economic burden, T2D increases the mortality mainly due to cardiovascular

diseases [2]. T2D patients have twice as much risk of developing heart failure (HF) independently of the presence of coronary heart disease [3, 4]. Growing evidence has led to describing a specific cardiac phenotype called diabetic cardiomyopathy, which associates left ventricular (LV) concentric hypertrophy [5, 6] with systolic and diastolic dysfunction [7].
Aortic stenosis (AS) is the most common valvular heart disease in Europe and grows as the population gets older [8]. T2D is frequently associated with chronic LV pressure overload such as AS. The prognosis of severe AS becomes significantly worse after the onset of symptoms [9] but also when the LV displays an increased LV mass [10], a significant diastolic dysfunction [11] and/or a systolic LV dysfunction [12, 13]; alterations that are also associated with diabetic cardiomyopathy. Clinical studies have indeed suggested an aggravating effect of T2D on cardiac function in patients with severe AS [14], together with an increased mortality [15]. However, only few studies have assessed the underlying mechanisms of T2D-induced alterations in the context of AS. At preclinical level, we reported that insulin resistance induced by a high-fat diet in mice worsened survival, cardiac hypertrophy and systolic/diastolic dysfunction under aortic constriction [16]. In patients with AS, T2D has been associated to a higher cardiomyocyte resting tension, an increased vascular advanced glycation end product deposition [14], an impaired myocardial energetics as reflected by the reduced phosphocreatine to ATP ratio [17], oxidative stress and metabolic dysfunction [18]. Altogether, these data suggest a strong role for metabolic alterations in the deleterious effect of T2D on LV remodeling and function in patients with severe AS.

Mitochondria play a central role in the regulation of cardiac energy metabolism: mitochondrial $Ca^{2+}$ concentration regulates the mitochondrial respiratory chain activity, ATP production and the activity of key mitochondrial dehydrogenases [19, 20], leading to the concept of the energetic regulation of the excitation-contraction coupling. Reticulum-mitochondria $Ca^{2+}$ coupling (also called MAM for mitochondria-associated reticulum membranes) is also involved in the control of the excitation-energetics coupling by regulating mitochondrial $Ca^{2+}$ handling [21, 22]. The mitochondrial $Ca^{2+}$ uniporter (mtCU) represents the key structure which controls $Ca^{2+}$ entry inside the mitochondrial matrix. A strategic positioning of the mtCU at the MAM interface has been demonstrated to enhance the excitation-energetics coupling [23]. Whether the reticulum-mitochondria $Ca^{2+}$ coupling and the mtCU are altered by T2D in AS patients remains to be investigated, as more is needed to know about the underlying biology of diabetic cardiomyopathy in patients, given the paucity of human tissue harvesting.

In this context, we aimed to explore the mechanisms associated with the deleterious effect of T2D on LV remodeling and function in patients with severe AS, preserved EF, and no additional heart disease. To this end, we combined a deep echocardiography phenotype of patients with severe AS±T2D referred for a valve replacement with transcriptomic and histological analyses of an intra-operative myocardial LV biopsy to test the

hypothesis that the deleterious effect of T2D on cardiac remodeling during AS is associated with mitochondrial $Ca^{2+}$ signaling alterations.

## Methods

### Trial design and patients

Consecutive patients with severe AS referred for surgical aortic valve replacement (AVR) were enrolled in a prospective bicentric (Lyon and Saint Etienne University Hospitals) cohort study called DIAPASON (Does type II dIAbetes influence Prognosis and/or left ventricular remodeling in patients with Aortic valve Stenosis referred for aOrtic valve replacemeNt, NCT01862237). The present study focused on preoperative analyses.

Patients addressed for aortic valve replacement were included, after informed consent, only when meeting the following criteria: age>18 years, severe AS (Aortic orifice surface<1 cm² or<0.6 cm²/m²), LVEF>50%, absence of overt heart disease or regional LV wall motion abnormalities, good acoustic window, affiliation to the social security system and no legal protection. Patients were excluded if they have type I diabetes or hyperglycemia without diabetes (fasting glucose between 1.1 and 1.25 g/L), chronic arrhythmia, significant coronary stenosis, history of cardiomyopathy including myocardial infarction, a more than mild other valvular diseases (mitral valve disease or aortic regurgitation), kidney failure (CI<30 mL/mn) or uncontrolled hypertension (>180/100 mmHg).

Patients were considered T2D if under anti-diabetic medication and/or with fasting glucose≥126 mg/dL (6.99 mmol/L). Control patients (non-diabetic patients) were defined by fasting blood sugar<110 mg/dL (6.11 mmol/L) and without any anti-diabetic medication.

Clinical data were collected at the inclusion. A complete physical examination was performed, including height, weight, blood pressure, and heart rate measurements. Blood samples were taken for routine biochemical analysis of HbA1c, brain natriuretic peptide, creatinine levels and lipid profile, and for subsequent collection.

Resting transthoracic echocardiography was performed using commercially available ultrasound systems (Vivid E9 or E95, General Electric). Images were digitally stored.

A LV myocardial biopsy was collected from the septum base during the aortic valve surgery. The biopsy was cut in two halves: one was formalin-fixed for histological analyses, and the other was snap-frozen in liquid nitrogen for mRNA analyses. The sample size for each endpoint is listed in Supplemental Table 1.

## Measurements of biomarkers concentrations

Serum samples were stored at – 80 °C. The concentration level of different biomarkers was analyzed with enzyme-linked immunosorbent assay (ELISA) in serum
with commercially available kits: insulin, leptin, FABP3, TIMP1, galectin 3, MMP9, S100B, Serpin, IL-6, ST2, CXCL9, CXCL10 (DuoSet ELISA by R&D Systems) and Endothelin 1 (QuantiGloTM ELISA).

## Echocardiography analysis

Echocardiographic studies were blindly analyzed offline (EchoPac, GE Vingmed) at the end of the inclusions.

Aortic valve stenosis severity was evaluated using mean aortic gradient, aortic valve (AV) area (AVA) based on the continuity-equation calculation [24] and the VTI ratio ($VTI_{LVOT}/VTI_{AV}$).

Valvuloarterial impedance (Zva), which represents the global systolic load imposed on the LV, was also estimated using the following formula: $Zva^{2.04}=(\text{mean aortic gradient}+\text{SBP})/(\text{SV}/\text{height}^{2.04})$.

Left ventricular remodeling was assessed following current guidelines [25].

Left ventricular end-diastolic and end-systolic volume (LVED and LVES) were calculated with the biplane Simpson method. Posterior wall thickness (PWT), interventricular septum thickness (IVST), and left ventricular end-diastolic diameter (LVEDD) were measured in parasternal long-axis views in 2D.

The left ventricular mass was assessed in 2D and 3D echocardiography. 2D left ventricular mass in grams (2D LVM) was calculated using the cube formula: $2D\ LVM=0.8×1.04\ ((IVST+LVEDD+PWT)3 - LVEDD3)+0.6$.

Three-dimensional LVM was measured on adequate apical acquisitions performed on 3 to 4 consecutive cardiac cycles (frame rate>25) during a brief apnea. 3D LV mass=LV epicardial volume – LV endocardial volume×1.05=LV myocardial volume×1.05. LV mass was further indexed to height to allometric power of 2.7 [26–28].

The left ventricular systolic function was assessed using left ventricle ejection fraction (LVEF %) using the biplane Simpson method, and global Longitudinal Strain (GLS) was measured from the three standard apical views after optimizing image quality, maximizing frame rate, and minimizing foreshortening. If the regional tracking was suboptimal in more than two myocardial segments in a single view, the GLS value was not considered.

Diastolic function and LV filling pressure assessment followed current algorithm [29, 30]. Transmitral inflow was recorded using pulsed wave Doppler in the apical 4-chamber view to measure early (E) and late (A) mitral inflow velocities. Early diastolic velocity was assessed at the septal (septal e') and lateral (lateral e') sites of the mitral annulus using pulsed wave tissue Doppler imaging. The average value of e' was used to calculate E/e' ratio [31]. Left atrial volume LAVi was estimated by the biplane Simpson method and indexed to BSA and

to height² [32]. The atrial strain was assessed in 4 and 2 chamber view [33]. Left ventricular filling pressure was classified as normal, elevated, or indeterminate [30].

## Histological analysis of LV biopsies

Endomyocardial biopsies were fixed in 10% buffered formalin, paraffin-embedded, and cut at 4 µm for subsequent staining. Both qualitative and quantitative histological analyses were performed blindly.

## Qualitative analysis

Myocyte hypertrophy, immune infiltration (HES) and fibrosis (Sirius Red) were graded blindly using a qualitative scale (mild, moderate, severe) by a cardiovascular pathologist.

## Myocyte diameter

Wheat germ agglutinin immunostaining (ThermoFisher W11261, 0.02 mg/mL) was performed to manually measure the myocyte diameter at the nucleus level on Fiji (an image processing package, used with imageJ) using slides digitized at 40×.

## Fibrosis quantification

A custom macro on Fiji was used to semi-automatically quantify the percentage of collagen stained in red on Sirius Red-stained sections.

## TUNEL assay

Apoptosis was quantified with the TUNEL assay (Invitrogen C10618, AlexaFluor 594) following the manufacturer's instructions. The total cell number and number of apoptotic cells were semi-automatically quantified using Fiji on 10× images.

## Proximity ligation assay (PLA)

PLA was conducted to quantify the proximity between the reticular IP3R-receptor (ab5804, 1/20000) and the mitochondrial VDAC porin (ab14734, 1/40000), according to the manufacturer's instruction (Sigma). Images were taken on a BX63 microscope at 60×. Quantification of the number of dots per cell was performed semi-automatically on Fiji.

## Method and statistical analyses of gene expression

### RNA isolation and RNAseq

Samples were crushed into powder in liquid nitrogen. Total RNA extraction was performed using miRNeasy mini kit (Qiagen) following the manufacturer's instructions. Purity and concentrations were measured using Nanodrop 2000 (Ozyme), while integrity was checked using Bioanalyser (Agilent). Fifty-five samples with ≥100 ng total RNA and DV200>30% were further processed for sequencing using Lexogen QuantSeq 3
mRNA seq Library Prep kit (Illumina). Two samples were excluded due to low library quality. Fifty-three libraries were sequenced on an Illumina NextSeq 500, generating around 8 million 75 bp single-end reads per library. Bcl2-fastq (v.2.17.1.14) was used for demultiplexing. After suppression of 3 samples due to high duplication level and of 3 outliers identified by principal component analysis, 47 samples were included in the RNAseq data analysis (Supplemental Fig. 1; Supplemental Table 2).

## Analysis of differential gene expression

FastQC (v0.11.9) was used to check raw read quality. Adaptor removal was performed using Cutadapt (v4.0) with default parameters. Only 75 bp-long reads were kept. Good Phred scores (>30) were obtained in all the libraries. However, three libraries showed high duplication levels leading to their exclusion. RNAseq reads' alignment was performed using STAR (v2.7.5a) against the GRCHh38 reference genome. DEseq2 (v1.36.0) was used for differential gene expression identification starting from counts generated by STAR (v2.7.5a). PCA plot

<table><caption>**Table 1** Pre-operative baseline characteristics</caption><thead><tr><th>Variable</th><th>Non-diabetic n = 50</th><th>T2D n = 34</th><th>p Value</th></tr></thead><tbody><tr><td>Age (years)</td><td>68 [61; 72]</td><td>67 [63; 74]</td><td>ns</td></tr><tr><td>Women (N, %)</td><td>19 (38%)</td><td>13 (38%)</td><td>ns</td></tr><tr><td>Medical history</td><td></td><td></td><td></td></tr><tr><td>BMI</td><td>25 [24; 27]</td><td>29 [26; 32]</td><td>&lt;0.001</td></tr><tr><td>BSA (m²)</td><td>1.8 [1.7; 1.9]</td><td>1.9 [1.7; 2.1]</td><td>&lt;0.05</td></tr><tr><td>Hypertension (N, %)</td><td>20 (41%)</td><td>30 (88%)</td><td>&lt;0.001</td></tr><tr><td>Retinopathy</td><td>0 (NaN%)</td><td>3 (10%)</td><td>ns</td></tr><tr><td>Clinical evaluation</td><td></td><td></td><td></td></tr><tr><td>NYHA grade (N, %)</td><td></td><td></td><td>&lt;0.01</td></tr><tr><td>Class I</td><td>16 (32%)</td><td>2 (5.9%)</td><td></td></tr><tr><td>Class II</td><td>19 (38%)</td><td>14 (41.2%)</td><td></td></tr><tr><td>Class III</td><td>14 (28%)</td><td>14 (41.2%)</td><td></td></tr><tr><td>Class IV</td><td>1 (2%)</td><td>1 (2.9%)</td><td></td></tr><tr><td>Unknown</td><td>0 (0%)</td><td>3 (8.8%)</td><td></td></tr><tr><td>Blood pressure (mmHg)</td><td></td><td></td><td></td></tr><tr><td>SBP</td><td>129 [118; 142]</td><td>137 [130; 148]</td><td>ns</td></tr><tr><td>DBP</td><td>72 [66; 78]</td><td>73 [66; 79]</td><td>ns</td></tr><tr><td>Risk factors</td><td></td><td></td><td></td></tr><tr><td>Dyslipidaemia (N, %)</td><td>14 (28%)</td><td>23 (68%)</td><td>&lt;0.001</td></tr><tr><td>Smoker (N, %)</td><td>19 (38%)</td><td>15 (44%)</td><td>ns</td></tr><tr><td>Medications</td><td></td><td></td><td></td></tr><tr><td>Insulin (N, %)</td><td>0 (0%)</td><td>10 (29%)</td><td>&lt;0.001</td></tr><tr><td>ACEI/ARB (N, %)</td><td>13 (26%)</td><td>22 (65%)</td><td>&lt;0.001</td></tr><tr><td>Betablockers (N, %)</td><td>8 (16%)</td><td>12 (35%)</td><td>ns</td></tr><tr><td>Statins (N, %)</td><td>13 (26%)</td><td>27 (79%)</td><td>&lt;0.001</td></tr></tbody></table>

Data are presented as n (%) or median [25th; 75th percentile]. p value displayed for Fisher exact test was used for categorical variables and the Wilcoxon test was used for continuous variables. ns not significant

ACEI/ARB ratio of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers, BMI body mass index, BSA body surface area, DBP diastolic blood pressure, SBP systolic blood pressure

was performed in R using vast transformed counts for outlier identification. Three samples were excluded from the following analysis. Finally, data from forty-seven samples were used for Gene expression analysis after normalization using the DESeq2. Genes were considered differentially expressed using the 5% P value threshold for significance. Adjustment for covariates was performed using generalized linear models within DESeq2. Functional Enrichment analysis was determined with gProfiler using only the annotated genes from the Human genome as background gene set, and represented as networks using EnrichmentMap in Cytoscape 3.8.2. The detailed RNA-seq information is available in GSE236191 deposited in the NIH GEO database.

## Statistical analyses

Quantitative data were described using median, first and third quartiles and qualitative data were described using effectives, percentages. Non-parametric tests (Wilcoxon or Fisher exact test) were done to compare distribution between groups.

We used univariate and multivariate linear regressions to examine predictive factors of 3D LV mass index to height² and Global Longitudinal Strain. We used univariate and multivariate logistic regressions to examine predictive factors of left ventricular filling pressure. Finals models were estimated using a backward stepwise procedure based on the minimization of the AIC criterion.

Statistical significance was defined as p-value < 0.05. All statistical analyses were performed using the R statistical Software version 3.3.3.

## Results

### Baseline characteristics of study patients

Aortic valve replacements were performed in 84 patients, including 34 with T2D. Baseline characteristics, including comorbidities and treatment of the population, are displayed in Table 1. The median age was 67 IQR [54; 75], and the proportion of enrolled women (38%) did not differ between the two groups. Hypertension (p<0.01) and dyslipidemia (p<0.01) coexisted more frequently in T2D patients. T2D patients had a greater BMI (p<0.01) and BSA (p<0.05). Renal function was normal and similar between groups (Supplemental Table 3).

Most T2D patients were treated with oral antidiabetic drugs (24 with metformin or sulfonylureas). Ten patients (29%) with T2D received insulin. T2D patients were more frequently under ACEI/ARB and statins than non-diabetics. Only three T2D patients had diabetic retinopathy.

NYHA states differed between groups with more T2D patients in class III NYHA than non-diabetic patients. However, BNP levels were not significantly different (Table 1, Supplemental Table 3).
## T2D patients had similar AS severity but displayed worse cardiac remodeling and function than non-diabetics

Aortic mean gradient, VTI ratio, AVA, and cardiac index were similar between both groups. Valvuloarterial impedance and stroke volume index did not differ between groups (Table 2).

Considering LV remodeling, T2D patients displayed similar end-diastolic diameter and volume. T2D

presented an increased LV hypertrophy with a thicker PWT (p<0.05) and LV 3D mass (p<0.05), as compared to non-diabetic patients.

T2D patients also presented a worse LV systolic function with a lower LVEF (61 [57; 64] vs 64 [58; 69] %, p<0.05), nevertheless remaining preserved, and a lower global longitudinal strain (15 [13; 17] vs 18 [17; 19] %, p<0.001) (Table 2).

<table><caption>**Table 2** Echocardiographic parameters</caption><thead><tr><th>Variable</th><th>Non-diabetic</th><th>T2D</th><th>p Value</th></tr></thead><tbody><tr><td>Aortic hemodynamic parameters</td><td></td><td></td><td></td></tr><tr><td>Aortic mean gradient (mmHg)</td><td>51 [48; 64]</td><td>57 [47; 68]</td><td>ns</td></tr><tr><td>Aortic permeability index</td><td>0.20 [0.18; 0.23]</td><td>0.20 [0.19; 0.24]</td><td>ns</td></tr><tr><td>AVA (cm²)</td><td>0.72 [0.66; 0.82]</td><td>0.79 [0.64; 0.89]</td><td>ns</td></tr><tr><td>AVA indexed to BSA (cm²/cm²)</td><td>0.41 [0.36; 0.47]</td><td>0.39 [0.33; 0.49]</td><td>ns</td></tr><tr><td>AVA indexed to height<sup>2.04</sup> (cm²/m²<sup>2.04</sup>)</td><td>0.26 [0.23; 0.29]</td><td>0.26 [0.23; 0.32]</td><td>ns</td></tr><tr><td>SV (mL)</td><td>80 [73; 87]</td><td>75 [69; 91]</td><td>ns</td></tr><tr><td>Svi to BSA (mL/m²)</td><td>45.0 [40.1; 49.6]</td><td>41.1 [35.8; 48.2]</td><td>ns</td></tr><tr><td>Zva (mmHg/mL/m²)</td><td>4.2 [3.7; 4.9]</td><td>5.0 [3.8; 6.2]</td><td>ns</td></tr><tr><td>Zva<sup>2.04</sup> (mmHg/mL/m²<sup>2.04</sup>)</td><td>6.6 [6.0; 7.8]</td><td>7.7 [5.9; 9.2]</td><td>ns</td></tr><tr><td>Left ventricle remodeling</td><td></td><td></td><td></td></tr><tr><td>IVS (mm)</td><td>15 [13; 16]</td><td>15 [14; 16]</td><td>ns</td></tr><tr><td>PWT (mm)</td><td>13 [11; 15]</td><td>13 [13; 16]</td><td>&lt;0.05</td></tr><tr><td>LVEDD (mm)</td><td>41 [36; 47]</td><td>41 [36; 45]</td><td>ns</td></tr><tr><td>EDV (BS) (mL)</td><td>94.5 [67.5; 113.5]</td><td>93.0 [74.8; 114.8]</td><td>ns</td></tr><tr><td>EDV (BS) (mL/m²)</td><td>49.9 [38.5; 62.5]</td><td>49.0 [40.4; 58.4]</td><td>ns</td></tr><tr><td>ESV (BS) (mL)</td><td>33.0 [23.3; 45.3]</td><td>35.5 [29.3; 46.0]</td><td>ns</td></tr><tr><td>ESV (BS) (mL/m²)</td><td>18.5 [13.2; 24.5]</td><td>19.3 [15.3; 24.1]</td><td>ns</td></tr><tr><td>3D LVM (g)</td><td>158 [133; 177]</td><td>169 [154; 221]</td><td>&lt;0.05</td></tr><tr><td>3D LVM/height<sup>2.7</sup> (g/m²<sup>2.7</sup>)</td><td>39 [33; 45]</td><td>46 [38; 52]</td><td>&lt;0.05</td></tr><tr><td>Systolic function</td><td></td><td></td><td></td></tr><tr><td>LVEF %</td><td>64 [58; 69]</td><td>61 [57; 64]</td><td>&lt;0.05</td></tr><tr><td>GLS %</td><td>18 [17; 19]</td><td>15 [13; 17]</td><td>&lt;0.001</td></tr><tr><td>Mechanical dispersion</td><td>55 [46; 74]</td><td>61 [50; 74]</td><td>ns</td></tr><tr><td>LV radial strain (%)</td><td>54 [49; 61]</td><td>52 [39; 63]</td><td>ns</td></tr><tr><td>Diastolic function</td><td></td><td></td><td></td></tr><tr><td>E/e'</td><td>12.0 [10.0; 15.0]</td><td>13.0 [11.9; 17.1]</td><td>ns</td></tr><tr><td>LA strain max (%)</td><td>21 [18; 31]</td><td>24 [17; 25]</td><td>ns</td></tr><tr><td>LA strain &lt; 18%</td><td>6 (16%)</td><td>9 (38%)</td><td>ns</td></tr><tr><td>PAPS (mmHg)</td><td>31 [28; 35]</td><td>32 [29; 43]</td><td>ns</td></tr><tr><td>LAESV (mL)</td><td>60.5 [44.5; 83.3]</td><td>70.0 [62.0; 102.0]</td><td>&lt;0.01</td></tr><tr><td>LAESVI (mL/m²)</td><td>32.7 [25.6; 46.2]</td><td>38.7 [30.2; 51.8]</td><td>ns</td></tr><tr><td>LAEDVI (mL/m²)</td><td>18.4 [13.4; 29.3]</td><td>22.4 [17.8; 27.3]</td><td>ns</td></tr><tr><td>LAESVI/height<sup>2</sup></td><td>22.1 [16.01; 29.7]</td><td>26.0 [20.8; 36.7]</td><td>&lt;0.05</td></tr><tr><td>LVFP</td><td></td><td></td><td></td></tr><tr><td>Normal</td><td>33 (66%)</td><td>15 (47%)</td><td>ns</td></tr><tr><td>Indeterminate</td><td>4 (8%)</td><td>1 (3%)</td><td>ns</td></tr><tr><td>Elevated</td><td>13 (26%)</td><td>16 (50%)</td><td>&lt;0.05</td></tr></tbody></table>

Data are n (%) or median [25th; 75th percentile]. p value displayed for Fisher exact test was used for categorical variables and Wilcoxon test was used for continuous variables. ns not significant

AVA aortic valve area, Sv stroke volume, Svi stroke volume index, Zva valvuloarterial impedance, Zva<sup>2.04</sup> valvuloarterial impedance with stroke volume index to height<sup>2.04</sup>, EDV (BS) end-diastolic volume (biplane Simpson), ESV (BS) end-systolic volume (biplane Simpson), GLS global longitudinal strain, IVS interventricular septal end diastole, LAESV left atrial end systolic volume, LAEDVI left atrial end diastolic volume index, LAESVI left atrial end systolic volume index, LAESVI/height<sup>2.7</sup> left atrial end systolic volume index to height<sup>2.7</sup>, LVEDD left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVFP left ventricular filling pressure (ref. 2022), LVM left ventricular mass, PAPS pulmonary artery systolic pressure, PWT posterior wall thickness
Regarding diastolic function parameters, left atrial volume was larger in T2D patients, considering LAESVI and LAEDVI indexed to height (as recommended in overweight patients). PAPs and E/e' ratio did not differ between both groups. LV atrial reservoir strain did not differ between groups but LV atrial reservoir strain tended to be more often <18% in T2D patients. Half of the T2D patients had elevated LVFP compared to only 26% of the non-diabetic patients (p<0.05, Table 2).

## T2D was independently associated with impaired systolic function

In the univariate analysis, including age, sex, hypertension, obesity, and AS severity, only BMI and T2D were associated with LV mass. In multivariate analyses, neither

<table><caption>**Table 3** Multivariate analyses on LV mass, GLS and LV filling pressure</caption><thead><tr><th>Parameter</th><th>Univariate B coef (95% CI)</th><th>p value</th><th>Multivariate B coef (95% CI)</th><th>p Value</th></tr></thead><tbody><tr><td colspan="5">3D LV mass index to height<sup>2,7</sup></td></tr><tr><td>T2D</td><td>5.57 (0.52-10.62)</td><td>&lt;0.05</td><td>0.9<br>(-6.45-8.24)</td><td>ns</td></tr><tr><td>Age</td><td>0.12 (-0.16-0.39)</td><td>ns</td><td></td><td></td></tr><tr><td>Sex (women)</td><td>1.26 (-3.71-6.23)</td><td>ns</td><td></td><td></td></tr><tr><td>PAS</td><td>0.09 (-0.05-0.23)</td><td>ns</td><td>0.07<br>(-0.07-0.21)</td><td>ns</td></tr><tr><td>BMI</td><td>0.58 (0.02-1.14)</td><td>&lt;0.05</td><td>0.62<br>(-0.3-1.54)</td><td>ns</td></tr><tr><td>Aortic mean gradient</td><td>0.1 (-0.09-0.28)</td><td>ns</td><td></td><td></td></tr><tr><td colspan="5">Global longitudinal strain</td></tr><tr><td>T2D</td><td>-2.64 (-3.73 to<br>-1.55)</td><td>&lt;0.001</td><td>-2.04 (-3.27<br>to -0.8)</td><td>&lt;0.001</td></tr><tr><td>Age</td><td>-0.01<br>(-0.08-0.06)</td><td>ns</td><td></td><td></td></tr><tr><td>Sex (women)</td><td>0.57 (-0.65-1.8)</td><td>ns</td><td></td><td></td></tr><tr><td>PAS</td><td>-0.03<br>(-0.06-0.01)</td><td>ns</td><td>-0.02<br>(-0.05-0.01)</td><td>ns</td></tr><tr><td>BMI</td><td>-0.09<br>(-0.23-0.05)</td><td>ns</td><td></td><td></td></tr><tr><td>Aortic mean gradient</td><td>0 (-0.04-0.05)</td><td>ns</td><td></td><td></td></tr><tr><td colspan="5">Left ventricular filling pressure</td></tr><tr><td>T2D</td><td>2.71 (1.05-7.17)</td><td>&lt;0.05</td><td>1.96<br>(0.67-5.74)</td><td>ns</td></tr><tr><td>Age</td><td>1.04 (0.99-1.1)</td><td>ns</td><td>1.04 (0.99-1.1)</td><td>ns</td></tr><tr><td>Sex (women)</td><td>1.48 (0.58-3.82)</td><td>ns</td><td></td><td></td></tr><tr><td>PAS</td><td>1.02 (0.99-1.04)</td><td>ns</td><td></td><td></td></tr><tr><td>BMI</td><td>1.1 (1-1.23)</td><td>ns</td><td>1.07<br>(0.96-1.21)</td><td>ns</td></tr><tr><td>Aortic mean gradient</td><td>0.98 (0.94-1.02)</td><td>ns</td><td></td><td></td></tr></tbody></table>

OR ratio used to binary variable and B coefficient for continued variable. Multivariate linear (B coef) and logistic (OR) regression with top-down stepwise procedure

ns not significant

BMI nor T2D remained significantly associated with LV mass.

In the univariate analysis, only T2D was significantly associated with LV filling pressure, but not in the multivariate analysis.

In the univariate analysis, T2D and systolic arterial pressure were associated with GLS and only T2D remained independently associated with GLS in the multivariate analysis (Table 3).

## Increased levels of T2D circulating markers correlate with the T2D-induced cardiac remodeling and dysfunction in AS patients

We evaluated the serum circulating level of known markers of T2D. As expected, leptin as a mediator of long-term regulation of energy balance/food intake and FABP3, involved in lipid metabolism, were significantly increased in T2D compared to non-diabetic patients (Fig. 1A, B). Leptin level showed a modest but significant correlation with the diastolic dysfunction parameters (LA strain max r=-0.23, p=0.01; LAESVI r=0.17, p<0.05), and FABP3 with 3D LVM/height<sup>2,7</sup> (r=0.1057, p<0.05).

Endothelin-1, a vasoconstrictor peptide, was significantly increased in the T2D group (Fig. 1C) and correlated with hypertrophy and systolic dysfunction (3D LVM/height<sup>2,7</sup>: r=0.27, p<0.001; GLS: r=-0.25, p<0.01).

Inflammatory and fibrotic circulating markers were not different between both groups (Supplemental Fig. 2).

## T2D triggers distinct transcriptomic myocardial signatures in AS patients

The filtered RNAseq read-set identified 15,434 genes. Among them, 1029 genes were significantly differentially expressed between non-diabetic and T2D patients (Supplemental Table 4). Principal component analysis based on these 1029 genes revealed a segregation along the first dimension (PC1: 28.3%) between the non-diabetic and T2D patients (Fig. 2A). To identify which biological processes were affected, we performed an enrichment analysis focusing either on the up-regulated or the down-regulated genes. Only biological process GO annotations presenting an adjusted p value<0.05 were considered as affected and were displayed on the enrichment maps (Fig. 2B, C).

Functional annotations significantly downregulated in T2D patients relate to mitochondrial respiratory chain organization and function, mitochondrial organization, amino acid metabolism, and regulation of muscle contraction (Fig. 2B).

The significantly upregulated pathways in T2D gather regulation of inflammation (leucocyte activation, neutrophil migration), extracellular matrix organization, endothelial function and angiogenesis, and adaptation to cardiac hypertrophy (Fig. 2C).
<figure><img src="image_16.png" /><figcaption>**Fig. 1** T2D increased circulating levels of metabolic markers in AS patients. Measurement of circulating serum biomarkers of diabetic cardiomyopathy focusing on leptin (A), FABP3 (B) and Endothelin 1 (C). Statistical analyses: Wilcoxon test. \*\*p < 0.01; \*\*\*p < 0.001</figcaption></figure>

## Influence of T2D covariates on gene expression

To test the influence of T2D covariates on gene expression changes, we used mixed linear models adjusting for age, BMI, hypertension, sex or all the 4. List of genes considered as differentially expressed were analyzed for biological pathways analysis. Regarding up-regulated genes, including covariates in the gene expression statistical model did not change the pathway enrichment (Fig. 3A). As for the downregulated gene pathways, the mitochondrial respiratory chain process and mitochondrial organization remained independently associated with T2D. However, the regulation of cardiac muscle contraction, the amino acid metabolism, and the mitochondrial transport, were no longer significantly associated with T2D after adjusting for covariates, mostly after adjustment with hypertension and age (Fig. 3B).

## Cardiac hypertrophy and mitochondrial dysfunction as main canonical signaling pathways induced by T2D

We next applied QIAGEN's Ingenuity® Pathway Analysis (IPA) tool to our DEG dataset. Cardiac hypertrophy signaling appeared as an upregulated pathway (Fig. 4). Endothelin-1, its membrane receptor and IGF1 gene expressions were significantly upregulated by T2D, leading to a predicting activation of concentric hypertrophic cardiomyopathy pathways (Fig. 4, point A). In parallel, an inhibition of Ca²⁺ signaling was involved on this pathway (Fig. 4, point B), notably by a decreased gene expression of a L-type Ca²⁺ channel (CACNA1A, Table 4), and at the level of the sarco-endoplasmic reticulum with a decreased gene expression of ryanodine receptor (RyR) (Table 4), and a predicted inhibition of both the

sarco-endoplasmic reticulum Ca²⁺ ATPase (SERCA) and the calmodulin gene expression.

Additionally, canonical signaling pathway analysis by IPA revealed a downregulation of mitochondrial signaling by T2D (Fig. 5). Several genes were significantly downregulated for complexes I, III and IV of the respiratory chain, as well as in the ATP synthase (Table 4). In parallel, a modification of mitochondrial Ca²⁺ signaling is displayed (Fig. 5). A decreased gene expression of a voltage-dependent calcium channel (CACNA1A, a L type Ca²⁺ channel, Table 4) is observed at the plasma membrane, predicted to decrease Ca²⁺ signaling up to mitochondria. Among the porins in the outer mitochondrial membrane, only VDAC3 tended to display a gene expression reduction by T2D. Concerning the mtCU in the inner mitochondrial membrane, both the pore-forming protein MCU and its negative dominant isoform MCUb were significantly increased at the gene level in T2D myocardium, while its regulatory proteins, MICU1 and MICU3, were downregulated (Table 4). Altogether, these changes led to a reduced MICU1/MCU ratio (1.77 [1.03; 2.26] vs 2.37 [1.68; 3.46], p<0.05) and an increased MCU/EMRE ratio (0.30 [0.23; 0.41] vs 0.23 [0.16; 0.28], p<0.01) without significant change in the MICU1/MICU2 and MCU/MCUb ratios. This is associated with an annotated "inconsistent finding": the mtCU gene remodeling (reduced MICU1/MCU ratio) is predicted to increase the mitochondrial Ca²⁺ uptake [34]. However, since the cytosolic Ca²⁺ signaling is predicted to be decreased, the increased mitochondrial Ca²⁺ uptake may partially compensate for the reduced mitochondrial Ca²⁺ signaling, therefore leading to a predicted inhibition of permeability transition (Fig. 5) with a significantly reduced gene
<figure><img src="image_17.png" /></figure>

<figure><img src="image_18.png" /></figure>

<figure><img src="image_19.png" /><figcaption>**Fig. 2** Myocardial transcriptomic changes induced by T2D in AS patients. RNAseq was performed on the myocardial biopsies. **A** Principal component analysis using the 1029 genes differentially expressed between non-diabetic (grey squares) and T2D (purple circles) patients. The bigger square and circle represent the gravity center for each cluster. **B, C** Enrichment maps displaying the significantly down- (B) or up-regulated (C) GO biological processes in T2D patients versus non-diabetics. Node color intensity is proportional to enrichment significance (Fisher exact P value after Benjamini-Hochberg (BH) adjustment for multiple comparisons). Relevant clusters of functionally related gene-sets were manually circled and assigned a label, based on suggested annotations by AutoAnnotate (Cytoscape)</figcaption></figure>

expression of ANT3 and components of ATP synthase, as proposed constituents of the permeability transition pore [35], while its regulator Cyclophilin D tended to be increased (Table 4).

## Tissue validation of T2D-induced cardiomyocyte hypertrophy, apoptosis and structural reticulum-mitochondria $Ca^{2+}$ uncoupling

To assess the relevance of the altered signaling pathways identified at the gene level, we performed a histological analysis on LV myocardium from patients of both groups. Qualitative evaluation of cardiomyocyte hypertrophy on H&E-stained sections revealed hypertrophy in both groups with more grade 2–3 (severe hypertrophy) in T2D patients (Supplemental Fig. 3A, B). Quantitative

measurements by WGA staining showed an increased cardiomyocyte diameter in the T2D LV myocardium compared to controls (17 [15; 2] vs. 12 [11; 15] µm, p<0.001, Fig. 6A).

TUNEL assay showed a tendency of an enhanced proportion of apoptotic cells in the T2D myocardium compared to non-diabetic ones (1.46 [0.98; 2.49] vs. 1.17 [0.71; 1.9] %, p=0.051, Fig. 6B).

The extent of fibrosis and inflammatory cell infiltration appeared similar between both groups at this stage, by either qualitative or quantitative analyses (Supplemental Fig. 3C–F).

Assessment of structural $Ca^{2+}$ coupling between the reticulum and mitochondria, at the level of the VDAC/Grp75/IP3R $Ca^{2+}$ channeling complexes involved in
<figure><img src="image_20.png" /><figcaption>**Fig. 3** Effect of comorbidities on differentially expressed T2D genes. Bubble plots represent for each main cluster identified in Fig. 2B, C, the enrichment of the most differentially expressed GO biological processes either up- (A) or down-regulated (B) in T2D patients versus non-diabetics, after adjustment for age, BMI, hypertension (HT), sex or all the 4 covariates (4 Cov)</figcaption></figure>

regulation of ATP production in cardiomyocytes [36], displayed a significant reduction in the number of IP3R-VDAC interactions in the diabetic myocardium (10 [9; 11] vs. 14 [9; 16] interactions per cell, p<0.05, Fig. 6C). Interestingly, the gene levels of IP3Rs, Grp75 and the MAM tether MFN2 were not changed by T2D (Table 4).

## Discussion

Combining RNA sequencing of LV biopsies from patients with severe AS, to a characterization of the non-invasive cardiac function allowed us to identify adverse LV remodeling and unique biological pathways associated with T2D during AS (Fig. 7). Our results strengthened
<figure><img src="image_21.png" /><figcaption>**Fig. 4** Cardiac hypertrophy signaling pathway in T2D myocardium identified by IPA. Relative changes in gene expression are depicted by graded shades of color coding: upregulated in red; downregulated in green. Predicted relationships, i.e. activation in orange, inhibition in blue and inconsistency in yellow, are depicted by colored arrows</figcaption></figure>
<table><caption>**Table 4** List of differentially expressed genes involved in mitochondrial signaling in T2D patients</caption><thead><tr><th>Protein name</th><th>Log2 Fold change</th><th>p Value</th></tr></thead><tbody><tr><td colspan="3">OXPHOS—Complex I</td></tr><tr><td>NDUFB9</td><td>-0.306</td><td>&lt;0.01</td></tr><tr><td>NDUFS2</td><td>-0.257</td><td>&lt;0.05</td></tr><tr><td>NDUFS6</td><td>-0.274</td><td>&lt;0.05</td></tr><tr><td>NDUFV3</td><td>-0.324</td><td>&lt;0.05</td></tr><tr><td>NDUFA13</td><td>-0.463</td><td>&lt;0.01</td></tr><tr><td>NDUFB2</td><td>-0.345</td><td>&lt;0.01</td></tr><tr><td>MT-ND1</td><td>-0.322</td><td>&lt;0.05</td></tr><tr><td>MT-ND2</td><td>-0.216</td><td>&lt;0.05</td></tr><tr><td>MT-ND3</td><td>-0.461</td><td>&lt;0.01</td></tr><tr><td>MT-ND4L</td><td>-0.488</td><td>&lt;0.01</td></tr><tr><td colspan="3">OXPHOS—Complex III</td></tr><tr><td>UQCR10</td><td>-0.276</td><td>&lt;0.05</td></tr><tr><td>UQCR11</td><td>-0.319</td><td>&lt;0.05</td></tr><tr><td colspan="3">OXPHOS—Complex IV</td></tr><tr><td>COX7C</td><td>-0.322</td><td>&lt;0.05</td></tr><tr><td>COX4I1</td><td>-0.251</td><td>&lt;0.05</td></tr><tr><td colspan="3">OXPHOS—Complex V</td></tr><tr><td>ATP5PF</td><td>-0.234</td><td>&lt;0.05</td></tr><tr><td>ATP5MJ</td><td>-0.298</td><td>&lt;0.01</td></tr><tr><td>ATP5MG</td><td>-0.241</td><td>&lt;0.05</td></tr><tr><td>ATP5ME</td><td>-0.284</td><td>ns</td></tr><tr><td>ATP5PO</td><td>-0.184</td><td>ns</td></tr><tr><td colspan="3">Reticulum-mitochondria coupling</td></tr><tr><td>ITPR3</td><td>0.102</td><td>ns</td></tr><tr><td>ITPR2</td><td>0.054</td><td>ns</td></tr><tr><td>ITPR1</td><td>0.123</td><td>ns</td></tr><tr><td>VDAC1</td><td>-0.089</td><td>ns</td></tr><tr><td>VDAC2</td><td>-0.097</td><td>ns</td></tr><tr><td>VDAC3</td><td>-0.165</td><td>ns</td></tr><tr><td>MFN2</td><td>-0.160</td><td>ns</td></tr><tr><td>HSPA9 (GRP75)</td><td>-0.064</td><td>ns</td></tr><tr><td>RYR2</td><td>-0.373</td><td>&lt;0.05</td></tr><tr><td>SERCA2</td><td>-0.051</td><td>ns</td></tr><tr><td>CACNA1A (L type Ca<sup>2+</sup> channel)</td><td>-0.436</td><td>&lt;0.05</td></tr><tr><td colspan="3">Mitochondrial calcium uniporter</td></tr><tr><td>MCU</td><td>0.413</td><td>&lt;0.01</td></tr><tr><td>MCUB</td><td>0.465</td><td>&lt;0.05</td></tr><tr><td>MICU1</td><td>-0.253</td><td>ns</td></tr><tr><td>MICU2</td><td>-0.049</td><td>ns</td></tr><tr><td>MICU3</td><td>-0.324</td><td>&lt;0.01</td></tr><tr><td>SMDT1 (EMRE)</td><td>-0.195</td><td>ns</td></tr><tr><td colspan="3">Permeability transition</td></tr><tr><td>SLC25A4 (ANT1)</td><td>0.043</td><td>ns</td></tr><tr><td>SLC25A5 (ANT2)</td><td>-0.040</td><td>ns</td></tr><tr><td>SLC25A6 (ANT3)</td><td>-0.221</td><td>&lt;0.05</td></tr><tr><td>PPIF (Cyp D)</td><td>-0.302</td><td>ns</td></tr></tbody></table>

ns not significant

the key role of mitochondrial calcium signaling in the diabetic human myocardium under chronic pressure overload, notably a reticulum-mitochondria structural Ca²⁺ uncoupling and a remodeling of the mtCU composition at gene level, paving the way for more focused functional studies to find potential therapeutic targets to limit the deleterious effect of T2D on cardiac function and remodeling in patients with severe AS.

## Mitochondrial dysfunction

The normal heart displays a metabolic flexibility regarding its substrate choice: mainly fatty acid oxidation, followed by glucose oxidation, requiring the TCA cycle and the oxidative phosphorylation as final steps. Several preclinical studies support a loss of metabolic flexibility in the diabetic heart, which remains mainly dependent on fatty acid oxidation [37]. In the context of AS, an association between altered myocardial energetics, i.e. reduced PCr/ATP ratios, and contractile dysfunction have been reported in T2D patients [17, 38, 39]. However, the underlying molecular mechanisms leading to this reduced ATP production in the human diabetic heart under chronic pressure overload remained unclear. Our transcriptomic analyses unraveled, in the context of AS, a significant T2D-specific downregulation of genes involved in mitochondrial respiratory chain assembly and mitochondrial membrane organization, that could account for the reduced mitochondrial ATP production via oxidative phosphorylation. Interestingly, T2D patients without AS have been shown to display impaired myocardial energetics [38, 39] and reduced mitochondrial respiration [40], thus suggesting the altered oxidative phosphorylation as a key dysfunction in the diabetic human heart, independently of additional disease.

Mitochondrial Ca²⁺ level is also crucial for the functioning of several matrix dehydrogenases. The structural reticulum-mitochondria Ca²⁺ uncoupling measured in the human T2D myocardium under severe AS may contribute to the reduced Ca²⁺ transfer to mitochondria and the subsequent alteration of mitochondrial Ca²⁺ level and energetics. In this regard, a murine model of diabetic cardiomyopathy with preserved EF displayed a decreased reticulum-mitochondria Ca²⁺ coupling as a critical trigger of cardiac dysfunction concomitantly to an increased cytosolic Ca²⁺ level [41]. Interestingly, at gene level, we measured a decreased expression of both L-type Ca²⁺ channel and RyR in the human diabetic myocardium of AS patients: this decrease could be considered as an attempt to counteract the increased cytosolic Ca²⁺ level in T2D hearts. Our RNAseq analysis also unraveled an increased MCU level and a trend towards a decreased MICU1 expression, leading to a reduced MICU1/MCU ratio, potentially leading to alteration of the mtCU protein composition. A lower MICU1/MCU ratio has been
<figure><img src="image_22.png" /><figcaption>**Fig. 5** IPA analysis of mitochondrial signaling pathway alteration induced by T2D. Relative changes in gene expression are depicted by graduated shades of color coding: upregulated in red; downregulated in green. Predicted relationships, i.e. activation in orange, inhibition in blue and inconsistency in yellow, are depicted by colored arrows</figcaption></figure>

shown to reduce the mtCU threshold [34] and favor mitochondrial Ca²⁺ uptake and ultimately overload [42]. An increased MICU1/MCU protein ratio has been demonstrated in human end-stage failing hearts, as a possible maladaptation to the HFrEF-induced mitochondrial Ca²⁺ overload [43]. Therefore, in the myocardium of T2D patients with severe AS, the reduced mitochondrial Ca²⁺ level and ensuing energetics due to the reticulum-mitochondria Ca²⁺ uncoupling, may be in part compensated by the remodeling of the mtCU at the gene level, i.e. a reduced MICU1/MCU ratio favoring the increased mitochondrial Ca²⁺ uptake. However, to avoid that this compensation becomes maladaptive over time and triggers mitochondrial Ca²⁺ overload and cell death, the measured increase in MCUb gene expression and decrease in MCU/EMRE ratio may act as safekeepers of a maladaptive compensatory remodeling of the mtCU.

Collectively, our study reveals alterations both at the level of the respiratory chain and of the mitochondrial Ca²⁺ signaling in the diabetic myocardium of patients with AS, as potential main contributors to the cardiac metabolic remodeling observed during diabetic cardiomyopathy [44].

## Cardiac hypertrophy

In our study of patients with severe AS but no other heart disease, we found that participants with T2D had a more pronounced LV hypertrophy than non-diabetic patients on echocardiography (LV concentric hypertrophy), which was further confirmed at the cellular level by an enhanced cardiomyocyte diameter. In the particular setting of AS, Paget et al. specifically addressed the impact of metabolic syndrome on LV remodeling in patients with mild to moderate AS but did not perform any tissue analysis as patients were not subjected to surgery. They reported an independent association between metabolic syndrome and LV concentric hypertrophy and dysfunction. In our study, in univariate but not in multivariate analysis, both T2D and BMI were associated with 3D LV mass. Therefore, it is possible that visceral obesity also participates to this increased LV hypertrophy. In previous works, FABP3 has been related to the control of cardiac insulin resistance [45] and fatty acid uptake [46], but also as an independent predictor for the occurrence of all-cause and CV mortality in T2D patients with HF [47]. In our study, the fatty acid binding protein FABP3 displayed significantly increased serum concentration in the T2D
<figure><img src="image_23.png" /><figcaption>**Fig. 6** Histological validation of myocardial alterations induced by T2D in AS patients. **A** Measurement of cardiomyocyte diameter, an index of cell hypertrophy. Upper: representative image of WGA staining. Lower: quantification of cell diameter. Magnification: 40x. **B** Analysis of apoptosis. Upper: typical image of TUNEL assay, showing nuclei in blue and apoptotic cells in red. Lower: quantification of the percentage of apoptotic cells. Magnification: 10x. **C** Proximity ligation assay to evaluate the proximity between the reticular IP3-receptor and the mitochondrial porin VDAC. Upper: representative picture of PLA between IP3R and VDAC. Nuclei in blue and IP3R-VDAC interactions in red. Lower: quantification of the number of interactions between IP3R and VDAC per cell. Magnification: 60x. Statistical analyses: Fisher and Wilcoxon tests. ns not significant; \*p < 0.05; \*\*\*p < 0.0001</figcaption></figure>

group and, interestingly, correlated positively with the 3D LV mass.

Concomitantly to a significantly increased cardiomyocyte hypertrophy in the T2D myocardium, our transcriptomic analysis revealed an upregulation of genes involved in regulating cardiac muscle hypertrophy specifically driven by T2D. ET-1 was increased at both circulating and myocardial gene levels in T2D patients, and correlated with the increased heart weight. Canonical pathway analysis indeed supports an activation of the concentric cardiac hypertrophy signaling pathway by ET-1 in the diabetic myocardium from AS patients.

Mitochondrial dysfunction has also been linked to cardiac hypertrophy in several animal models [48]. A multi-omics study in patients with hypertrophic cardiomyopathy, including RNAseq, suggested defective ATP production as the primary contributor of hypertrophy [49]. Our data also support a critical role for the mitochondrial oxidative phosphorylation in cardiac hypertrophy since genes involved in respiratory chain formation were specifically downregulated in T2D patients. Additionally, single-cell transcriptional analysis revealed a decreased number of genes involved in the formation of the MAM in cardiomyocytes during the time course of hypertrophy induced by TAC in mice [50]. A reduced co-immunoprecipitation between IP3R and VDAC was reported in the hypertrophic mouse heart under TAC

conditions [51]. Our histological analysis showed fewer interactions between IP3R and VDAC in the myocardium from T2D patients with severe AS, supporting a structural reticulum-mitochondria $Ca^{2+}$ uncoupling that may also play a role in triggering cardiac hypertrophy.

Altogether, our findings advocate for a T2D effect on cardiac hypertrophy in patients with pressure overload, going from gene regulation to altered cellular architecture.

## Study limitations

In our study, we could not match patients based on comorbidities due to the goal of the study, i.e. evaluate the impact of T2D on severe AS; but patients were matched on demographics. A T2D effect still remained after comorbidity adjustment, for left ventricular systolic function (GLS) and the transcriptomic signature. Although both groups did not display the same number of patients, one strength of our study is to have a relatively large number of patients in each group, with all the measurements, from clinical to molecular, performed on almost all the patients, therefore allowing a comprehensive analysis of the LV function structure and molecular composition. As we did not perform single-cell RNAseq, changes in cellular composition may have caused a bias in our analysis. Moreover, the transcriptomic analysis does
<figure><img src="image_24.png" /><figcaption>**Fig. 7** Central scheme depicting the T2D-specific biological processes associated with T2D-induced left ventricular dysfunction in patients with severe aortic stenosis. ETC electron transport chain, *ET-1* endothelin-1, FABP3 fatty-acid binding protein 3, GLS global longitudinal strain, LVFP left ventricular filling pressure, MAM mitochondria-associated membranes</figcaption></figure>

not necessarily reflect protein changes, but is of great rel-
evance to digging out the underlying mechanisms.

Thus, further studies are needed to decipher the func-
tional changes in a new cohort with fresh cardiac biops-
sies. Nevertheless, we also performed LV histological
analyses, which complemented the gene expression
changes with structural data, notably the reticulum-
mitochondria Ca²⁺ uncoupling and the cardiomyocyte
hypertrophy.

**Conclusions**

Collectively, our data—from cardiac imaging phenotyp-
ing to tissue analysis—strongly support a crucial role for
mitochondrial Ca²⁺ signaling in T2D-induced cardiac
dysfunction during severe AS. We reported a structural
reticulum-mitochondria Ca²⁺ uncoupling together with

a remodeling of the mtCU composition at gene level in
the LV of AS patients with T2D and preserved EF: impor-
tantly, these alterations may not be confined to pressure-
overload patients and thus be encountered in patients
with diabetic cardiomyopathy evolving towards meta-
bolic HFpEF. With the recent development of screening
strategies to identify new mtCU modulators [52] or to
repurpose FDA-approved drugs [53], restoration of mito-
chondrial Ca²⁺ signaling opens a new therapeutic avenue
to be tested in animal models and further human cardiac
biopsies in order to propose new treatments for T2D
patients suffering from AS.

**Abbreviations**

<table>
  <tr>
    <td>ANT3</td>
    <td>Adenine nucleotide translocase 3</td>
  </tr>
  <tr>
    <td>AS</td>
    <td>Aortic stenosis</td>
  </tr>
  <tr>
    <td>ATP</td>
    <td>Adenosine triphosphate</td>
  </tr>
</table>
<table><tr><td>AV</td><td>Aortic valve</td></tr><tr><td>AVA</td><td>Aortic valve area</td></tr><tr><td>AVR</td><td>Aortic valve replacement</td></tr><tr><td>BMI</td><td>Body mass index</td></tr><tr><td>BNP</td><td>Brain natriuretic peptide</td></tr><tr><td>BSA</td><td>Body surface area</td></tr><tr><td>Ca<sup>2+</sup></td><td>Calcium</td></tr><tr><td>CACNA1A</td><td>Calcium voltage-gated channel subunit alpha 1A</td></tr><tr><td>CXCL9</td><td>Chemokine (C-X-C motif) ligand 9</td></tr><tr><td>EF</td><td>Ejection fraction</td></tr><tr><td>ELISA</td><td>Enzyme-linked immunosorbent assay</td></tr><tr><td>EMRE</td><td>Essential MCU regulator</td></tr><tr><td>ET-1</td><td>Endothelin-1</td></tr><tr><td>FABP3</td><td>Fatty acids binding protein 3</td></tr><tr><td>GLS</td><td>Global longitudinal strain</td></tr><tr><td>GO</td><td>Gene ontology</td></tr><tr><td>Grp75</td><td>75-kDa glucose-regulated protein</td></tr><tr><td>HbA1c</td><td>Glycated hemoglobin</td></tr><tr><td>HES</td><td>Hematoxylin eosin safran</td></tr><tr><td>HF</td><td>Heart failure</td></tr><tr><td>HFpEF</td><td>Heart failure with preserved ejection fraction</td></tr><tr><td>HFrEF</td><td>Heart failure with reduced ejection fraction</td></tr><tr><td>IL-6</td><td>Interleukin 6</td></tr><tr><td>IP3R</td><td>Inositol 1,4,5-triphosphate receptor</td></tr><tr><td>IPA</td><td>Ingenuity pathway analysis</td></tr><tr><td>IQR</td><td>Interquartile range</td></tr><tr><td>IVST</td><td>Interventricular septal thickness</td></tr><tr><td>LAEDVI</td><td>Left atrial end diastolic volume index</td></tr><tr><td>LAESVI</td><td>Left atrial end systolic volume index</td></tr><tr><td>LAVi</td><td>Left atrial volume index</td></tr><tr><td>LV</td><td>Left ventricular</td></tr><tr><td>LVED</td><td>Left ventricular end diastolic</td></tr><tr><td>LVEDD</td><td>Left ventricular end diastolic diameter</td></tr><tr><td>LVEF</td><td>Left ventricular ejection fraction</td></tr><tr><td>LVES</td><td>Left ventricular end systolic</td></tr><tr><td>LVFP</td><td>Left ventricle filling pressure</td></tr><tr><td>LVM</td><td>Left ventricular mass</td></tr><tr><td>MAM</td><td>Mitochondria-associated reticulum membranes</td></tr><tr><td>MCU</td><td>Mitochondrial calcium uniporter</td></tr><tr><td>MCUb</td><td>Mitochondrial calcium uniporter b</td></tr><tr><td>MFN2</td><td>Mitofusin 2</td></tr><tr><td>MICU1</td><td>Mitochondrial calcium uptake family member 1</td></tr><tr><td>MMP9</td><td>Metalloproteinase 9</td></tr><tr><td>mRNA</td><td>Messenger ribonucleic acids</td></tr><tr><td>mtCU</td><td>Mitochondrial calcium uniporter</td></tr><tr><td>NYHA</td><td>New York heart association</td></tr><tr><td>PAPs</td><td>Pulmonary artery pressure</td></tr><tr><td>PC1</td><td>Principal component 1</td></tr><tr><td>PCA</td><td>Principal component analysis</td></tr><tr><td>PCr/ATP</td><td>Phosphocreatine/adenosine triphosphate ratio</td></tr><tr><td>PLA</td><td>Proximity ligation assay</td></tr><tr><td>PWT</td><td>Posterior wall thickness</td></tr><tr><td>RNAseq</td><td>Ribonucleic acid sequencing</td></tr><tr><td>RyR</td><td>Ryanodine receptor</td></tr><tr><td>S100B</td><td>Small calcium binding protein B</td></tr><tr><td>SBP</td><td>Systolic blood pressure</td></tr><tr><td>ST2</td><td>Suppression of tumorigenicity 2</td></tr><tr><td>SV</td><td>Systolic volume</td></tr><tr><td>T2D</td><td>Type 2 diabetes</td></tr><tr><td>TCA</td><td>Tricarboxylic acid cycle</td></tr><tr><td>TIMP1</td><td>TIMP metallopeptidase inhibitor 1</td></tr><tr><td>TUNEL</td><td>Terminal deoxynucleotidyl transferase dUTP nick end labeling</td></tr><tr><td>VDAC</td><td>Voltage-dependent anion channel</td></tr><tr><td>VTI</td><td>Velocity time integral</td></tr><tr><td>WGA</td><td>Wheat germ agglutinin</td></tr><tr><td>Zva</td><td>Valvuloarterial impedance</td></tr></table>

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12933-024-02329-5.

Supplementary material

**Acknowledgements**

We would like to thank Severine Crozes on the ProfileXpert platform (Lyon, France), Corinne Perrin from the Tissu-Tumorothèque Est platform (CRB HCL, Lyon, France) and Nathalie Dufay on the Neurobiotech platform (CRB HCL, Lyon, France, Biobank BB-0033-00046).

**Author contributions**

Conceptualization: H.T., C.B., G.D., M.Pa., M.C., E.M., N.M.; Investigation: M.C., E.M., G.S., M.Po., R.P., S.L., F.F., M.V., J.F.O., C.A., L.C., C.M., S.C., C.B., L.G., C.B., M.Pa., H.T.; Writing: M.C., H.T., M.Pa., E.M.; Manuscript reviewing: C.B., N.M., G.B., L.C.; Funding Acquisition: H.T., M.Pa.

**Funding**

This project was funded by the French Ministry of Health and Research National Program (n° IR-27-24) and a grant from the Société Française de Cardiologie (Bourse Cœur, Vaisseaux, Diabète 2011) to HT, and by a grant from the Fondation de France (n°00107048) and a grant from the Agence Nationale de la Recherche (ANR-20-CE14-0013-01) to MPa.

**Availability of data and materials**

The datasets generated and analysed during the current study are available in the repository GSE236191 deposited in the NIH GEO database (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE236191).

**Declarations**

**Ethics approval and consent to participate**

The ethics committee CPP Sud-Est III approved the study 2012-048B on November 2012.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

¹Explorations Fonctionnelles Cardiovasculaires, Hospices Civils de Lyon, 69500 Bron, France

²Laboratoire CarMeN - IRIS Team, INSERM, INRA, Université Claude Bernard Lyon-1, Univ-Lyon, 69500 Bron, France

³Service de Cardiologie, CHU Nord, 42100 Saint-Étienne, France

⁴Laboratoire d'anatomopathologie, Hospices Civils de Lyon, 69500 Bron, France

⁵Chirurgie Cardiaque, Hospices Civils de Lyon, 69500 Bron, France

⁶Centre d'investigation Clinique, Hospices Civils de Lyon, 69500 Bron, France

⁷INSERM U955, Université Paris-Est Créteil, Créteil, France

⁸Department of Physiology, AP-HP, Henri Mondor Hospital, FHU SENEC, Créteil, France

Received: 15 March 2024 / Accepted: 19 June 2024

Published online: 08 July 2024

**References**

1. https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf.

2. Rajbhandari J, Fernandez CJ, Agarwal M, Yeap BXY, Pappachan JM. Diabetic heart disease: a clinical update. World J Diabetes. 2021;12:383–406.

3. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34.

4. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83.
5. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000;101:2271-6.

6. Yoneyama K, Venkatesh BA, Wu CO, Mewton N, Gjesdal O, Kishi S, et al. Diabetes mellitus and insulin resistance associate with left ventricular shape and torsion by cardiovascular magnetic resonance imaging in asymptomatic individuals from the multi-ethnic study of atherosclerosis. J Cardiovasc Magn Reson. 2018;20:53.

7. Ernande L, Bergerot C, Rietzschel ER, De Buyzere ML, Thibault H, PignonBlanc PG, et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr. 2011;24:1268-75.e1.

8. lung B. A prospective survey of patients with valvular heart disease in Europe: the euro heart survey on valvular heart disease. Eur Heart J. 2003;24:1231-43.

9. Bach DS, Cimino N, Deeb GM. Unoperated patients with severe aortic stenosis. J Am Coll Cardiol. 2007;50:2018-9.

10. Stein EJ, Fearon WF, Elmariah S, Kim JB, Kapadia S, Kumbhani DJ, et al. Left ventricular hypertrophy and biomarkers of cardiac damage and stress in aortic stenosis. J Am Heart Assoc. 2022;11:e023466.

11. Guo Y, Sun M, Chen H, Kong D, Shu X, Pan C. Assessment of left ventricular diastolic function after transcatheter aortic valve implantation in aortic stenosis patients by echocardiographic according to different guidelines. Cardiovasc Ultrasound. 2020;18:3.

12. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg. 2006;82:2111-5.

13. Magne J, Cosyns B, Popescu BA, Carstensen HG, Dahl J, Desai MY, et al. Distribution and prognostic significance of left ventricular global longitudinal strain in asymptomatic significant aortic stenosis. JACC Cardiovasc Imaging. 2019;12:84-92.

14. Falcão-Pires I, Hamdani N, Borbély A, Gavina C, Schalkwijk CG, van der Velden J, et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation. 2011;124:1151-9.

15. Coisne A, Montaigne D, Ninni S, Lamblin N, Lemesle G, Delsart P, et al. Diabetes mellitus and cardiovascular mortality across the spectrum of aortic stenosis. Heart Br Card Soc. 2022;108:1815-21.

16. Raher MJ, Thibault HB, Buys ES, Kuruppu D, Shimizu N, Brownell A-L, et al. A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload. Am J Physiol-Heart Circ Physiol. 2008;295:H2495-502.

17. Jex N, Greenwood JP, Cubbon RM, Rider OJ, Chowdhary A, Thirunavukarasu S, et al. Association between type 2 diabetes and changes in myocardial structure, contractile function, energetics, and blood flow before and after aortic valve replacement in patients with severe aortic stenosis. Circulation. 2023;148:1138-53.

18. Martin-Núñez E, Gori-Olóriz M, Matilla L, Garaikoetxea M, Mourino-Alvarez L, Navarro A, et al. Influence of diabetes mellitus on the pathological profile of aortic stenosis: a sex-based approach. Cardiovasc Diabetol. 2023;22:280.

19. McCormack JG, Denton RM. Role of calcium ions in the regulation of intra-mitochondrial metabolism. Properties of the Ca²⁺-sensitive dehydrogenases within intact uncoupled mitochondria from the white and brown adipose tissue of the rat. Biochem J. 1980;190:95-105.

20. Moreno-Sánchez R, Hansford RG. Dependence of cardiac mitochondrial pyruvate dehydrogenase activity on intramitochondrial free Ca²⁺ concentration. Biochem J. 1988;256:403-12.

21. Rossini M, Filadi R. Sarcoplasmic reticulum-mitochondria kissing in cardiomyocytes: Ca²⁺, ATP, and undisclosed secrets. Front Cell Dev Biol. 2020;8:532.

22. Seidlmayer LK, Kuhn J, Berbner A, Arias-Loza P-A, Williams T, Kaspar M, et al. Inositol 1,4,5-trisphosphate-mediated sarcoplasmic reticulum-mitochondrial crosstalk influences adenosine triphosphate production via mitochondrial Ca²⁺ uptake through the mitochondrial ryanodine receptor in cardiac myocytes. Cardiovasc Res. 2016;112:491-501.

23. De La Fuente S, Fernandez-Sanz C, Vail C, Agra EJ, Holmstrom K, Sun J, et al. Strategic positioning and biased activity of the mitochondrial calcium unipporter in cardiac muscle. J Biol Chem. 2016;291:23343-62.

24. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22:1-23.

25. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and

the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14.

26. Cuspidi C, Meani S, Negri F, Giudici V, Valerio C, Sala C, et al. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives? J Hum Hypertens. 2009;23:728-34.

27. Pagé A, Dumesnil JG, Clavel M-A, Chan KL, Teo KK, Tam JW, et al. Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis. J Am Coll Cardiol. 2010;55:1867-74.

28. 2018 ESC/ESH Guidelines for the management of arterial hypertension|European Heart Journall|Oxford Academic. https://academic.oup.com/eurheartj/article/39/33/3021/5079119?login=false. Accessed 14 Mar 2024

29. Naguef SH, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29:277-314.

30. Smiseth OA, Morris DA, Cardim N, Cikes M, Delgado V, Donal E, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2022;23:e34-61.

31. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuer JA, Foster MC, et al. Guidelines for performing a comprehensive transthoriacic echocardiographic examination in adults: recommendations from the American society of echocardiography. J Am Soc Echocardiogr. 2019;32:1-64.

32. Davis EF, Croussillat DR, He W, Andrews CT, Hung JW, Danik JS. Indexing left atrial volumes: alternative indexing methods better predict outcomes in overweight and obese populations. JACC Cardiovasc Imaging. 2022;15:989-97.

33. Pathan F, D'Elia N, Nolan MT, Marwick TH, Negishi K. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2017;30:59-70.e8.

34. Paillard M, Csordás G, Szanda G, Golenár T, Debattisti V, Bartok A, et al. Tissue-specific mitochondrial decoding of cytoplasmic Ca²⁺ signals is controlled by the stoichiometry of MICU1/2 and MCU. Cell Rep. 2017;18:2291-300.

35. Frigo E, Tommasin L, Lippe G, Carraro M, Bernardi P. The haves and have-nots: the mitochondrial permeability transition pore across species. Cells. 2023;12:1409.

36. Szabadkai G, Bianchi K, Várnai P, De Stefani D, Wieckowski MR, Cavagna D, et al. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca²⁺ channels. J Cell Biol. 2006;175:901-11.

37. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in heart failure. Circ Res. 2021;128:1487-513.

38. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JWA, Bax JJ, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003;42:328-35.

39. Levelt E, Mahmud M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, et al. Relationship between left ventricular structural and metabolic remodelling in type 2 diabetes mellitus. Diabetes. 2016;65:44-52.

40. Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation. 2014;130:554-64.

41. Dia M, Gomez L, Thibault H, Tessier N, Leon C, Chouabe C, et al. Reduced reticulum-mitochondria Ca2+ transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy. Basic Res Cardiol. 2020;115:74.

42. Csordás G, Golenár T, Seifert EL, Kamer KJ, Sancak Y, Perocchi F, et al. MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca²⁺ unipporter. Cell Metab. 2013;17:976-87.

43. Paillard M, Huang K-T, Weaver D, Lambert JP, Elrod JW, Hajnóczky G. Altered composition of the mitochondrial Ca²⁺ unipporter in the failing human heart. Cell Calcium. 2022;105:102618.

44. Chong C-R, Clarke K, Levelt E. Metabolic remodelling in diabetic cardiomyopathy. Cardiovasc Res. 2017;113:422-30.

45. Shearer J, Fueger PT, Wang Z, Bracy DP, Wasserman DH, Rottman JN. Metabolic implications of reduced heart-type fatty acid binding protein in insulin resistant cardiac muscle. Biochim Biophys Acta. 2008;1782:586-92.
46. Murphy EJ, Barcelo-Coblijn G, Binas B, Glatz JFC. Heart fatty acid uptake is decreased in heart fatty acid-binding protein gene-ablated mice. J Biol Chem. 2004;279:34481-8.

47. Rodríguez-Calvo R, Granado-Casas M, de Pérez-Montes A, Julian MT, Domingo M, Codina P, et al. Fatty acid binding proteins 3 and 4 predict both all-cause and cardiovascular mortality in subjects with chronic heart failure and type 2 diabetes mellitus. Antioxidants. 2023;12:645.

48. di Facundo HTF, Brainard RE, de Caldas FRL, Lucas AMB. Mitochondria and cardiac hypertrophy. In: Santulli G, editor. Mitochondrial dynamics in cardiovascular medicine. Cham: Springer; 2017. p. 203-6.

49. Ranjbarvaziri S, Kooiker KB, Ellenberger M, Fajardo G, Zhao M, Vander Roest AS, et al. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation. 2021;144:1714-31.

50. Luan Y, Guo G, Luan Y, Yang Y, Yuan R. Single-cell transcriptional profiling of hearts during cardiac hypertrophy reveals the role of MAMs in cardiomyocyte subtype switching. Sci Rep. 2023;13:8339.

51. Wang Y, Li X, Xu X, Qu X, Yang Y. Transient receptor potential vanilloid type 1 protects against pressure overload-induced cardiac hypertrophy by promoting mitochondria-associated endoplasmic reticulum membranes. J Cardiovasc Pharmacol. 2022;80:430-41.

52. Arduino DM, Wettmarshausen J, Vais H, Navas-Navarro P, Cheng Y, Leimpek A, et al. Systematic identification of MCU modulators by orthogonal interspecies chemical screening. Mol Cell. 2017;67:711-23.e7.

53. De Mario A, Tosatto A, Hill JM, Kriston-Vizi J, Ketteler R, Vecellio Reane D, et al. Identification and functional validation of FDA-approved positive and negative modulators of the mitochondrial calcium uniporter. Cell Rep. 2021;35:109275.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.